PASH syndrome (pyoderma gangrenosum, acne, and suppurative hidradenitis) forms part of the spectrum of autoinflammatory diseases. We report an unusual case of PASH syndrome in a patient with end-stagerenal disease (ESRD) who was successfully treated with the tumor necrosis factor inhibitor, adalimumab. The case underscores the challenges associatedwith the treatment of PASH syndrome as well as the ongoing search to establish a genetic basis for the syndrome. Renal impairment has been reported in association with pyoderma gangrenosum but has notbeen described in PASH syndrome. We believe this to be the first reported case of a patient who developed PASH syndrome in the setting of ESRD.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Biologic management of PASH syndrome: A systematic review.
Arch Dermatol Res
November 2024
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Hidradenitis Suppurativa from a Multi-Omic Scope.
J Cutan Med Surg
November 2024
Rheumatology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain.
Article Synopsis
- * Genetic studies have identified issues with Notch signaling and inflammasome function in HS, while syndromic HS is linked to mutations in certain autoinflammatory syndromes like PAPA and PASH.
- * Research in proteomics and microbiome profiling highlights inflammatory pathways and a disturbed balance of bacteria in HS lesions, while metabolomic studies reveal imbalances in tryptophan and lipid metabolism, indicating potential bacterial involvement; however, establishing strong links across these
A complex case of PASH syndrome: pyoderma gangrenosum, acne, suppurative hidradenitis, and Crohn's disease in a 36-year-old smoker.
Ann Med Surg (Lond)
October 2024
Department of Dermatology and Venereology, Aleppo University Hospital, University of Aleppo.
Article Synopsis
- PASH syndrome is an autoimmune condition that causes skin problems like acne and painful sores, which get worse over time.
- A 36-year-old man had severe symptoms including skin ulcers and struggled to find effective treatments until he improved using Infliximab.
- Treating PASH syndrome is tricky because it can be linked to other health issues, and doctors need to try different therapies to see what works best for each patient.
PASH syndrome: A novel MEFV mutation variant with excellent response to adalimumab in a refractory case.
Int J Dermatol
January 2025
Reference Center in Rare and Difficult-to-diagnose Diseases (CERyD), Department of Internal Medicine, Hospital San Juan de Dios, La Plata, Argentina.
Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome: a single-institution case series with a focus on management.
Arch Dermatol Res
June 2024
Department of Dermatology, The Ohio State University Wexner Medical Center, 1328 Dublin Rd. Suite 100, Columbus, OH, 43212, USA.
Background: Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome is a rare condition characterized by clinical features of all three dermatologic conditions. The management of PASH syndrome is difficult, with no consensus on treatment guidelines. Since PASH syndrome can increase morbidity and adversely impact quality of life, better characterization of effective therapies is needed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!